Service ICAR, Centre Hospitalier Universitaire (CHU) Pitié-Salpêtrière, Paris, France; Nephrology Department, CHU Pitié-Salpêtrière, Paris, France.
Cancer. 2014 Jul 15;120(14):2158-63. doi: 10.1002/cncr.28709. Epub 2014 Apr 15.
Vemurafenib is a BRAF inhibitor that has become the cornerstone of metastatic or inoperable melanoma therapy since its approval in 2011 in the United States and 2012 in Europe. This targeted therapy has shown impressive results in terms of increased progression-free and overall survival as compared to dacarbazine. The safety profile did not include any renal manifestations at that time.
This report is the first case series of 8 patients who experienced significant to severe renal insufficiency under vemurafenib treatment.
This case series shows that vemurafenib may induce potentially severe acute renal failure, including renal sequelae and persistent kidney disease in some cases.
Further studies are needed to investigate the effects of vemurafenib on the kidneys. Meanwhile, renal function should be closely monitored in treated patients for early detection of any renal dysfunction occurrence. Cancer 2014;120:2158-2163. © 2014 American Cancer Society.
维莫非尼（vemurafenib）是一种 BRAF 抑制剂，自 2011 年在美国和 2012 年在欧洲获得批准以来，已成为转移性或不可手术性黑色素瘤治疗的基石。与达卡巴嗪相比，这种靶向治疗在无进展生存期和总生存期方面均显示出显著的效果。当时，其安全性特征不包括任何肾脏表现。
本报告是 8 例接受维莫非尼治疗后出现严重至重度肾功能不全患者的首个病例系列。
本病例系列表明，维莫非尼可能导致潜在的严重急性肾衰竭，包括在某些情况下的肾脏后遗症和持续性肾脏疾病。
需要进一步研究来探讨维莫非尼对肾脏的影响。同时，应密切监测接受治疗患者的肾功能，以便早期发现任何肾功能障碍的发生。癌症 2014；120：2158-2163。©2014 美国癌症协会。
